Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial

BACKGROUND: Liraglutide 3 mg was recently approved as an anti-obesity drug. Metformin is weight neutral, yet it could enhance the therapeutic index of GLP-1 agonist. We compared weight-lowering potential of liraglutide 1.2 mg in combination with metformin to liraglutide 3 mg monotherapy in obese PCO...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMC Endocr Disord
Hlavní autoři: Jensterle, Mojca, Kravos, Nika Aleksandra, Goričar, Katja, Janez, Andrej
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2017
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5286837/
https://ncbi.nlm.nih.gov/pubmed/28143456
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12902-017-0155-9
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky